【レポートの概要（一部）】
1. Report Overview
1.1 Global Cholesterol-Lowering Drugs Market Overview
1.2 Global Cholesterol-Lowering Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Cholesterol-Lowering Drugs
2.1 The Pharmaceutical Industry: A Brief Overview
2.2 Cholesterol: An Essential Lipid
2.3 The Functions of Cholesterol
2.4 Metabolism and Circulation of Cholesterol
2.5 The Role of Cholesterol in Heart Disease
2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
2.6.1 The IMPROVE-IT Study
2.7 The Role of Cholesterol in Heart Disease: The Controversy
2.8 Raising HDL Cholesterol: A Worthwhile Aim?
2.9 Causes of Hypercholesterolaemia
2.9.1 Atherosclerosis
2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
2.9.3 Familial Hypercholesterolaemia
2.10 Treatment of Hypercholesterolaemia
2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
2.10.2 US Treatment Guidelines for Hypercholesterolaemia
2.10.3 Lifestyle Changes
2.10.4 Drugs to Lower Cholesterol
2.10.5 Other Therapeutic Approaches
2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
2.11 Classification of Cholesterol-Lowering Drugs
2.11.1 Statins
2.11.2 Selective Cholesterol Absorption Inhibitors
2.11.3 Ion Exchange Resins
2.11.4 Fibrates
2.11.5 Other Cholesterol-Lowering Drugs
2.11.6 Novel Cholesterol-Lowering Drugs
2.11.7 PCSK9 Inhibitors
2.12 Phases of Clinical Trials
2.13 Scope of This Report
2.13.1 Products Excluded from This Report
2.14 Currency Exchange Rates in This Report
3. Cholesterol-Lowering Drugs: World Market 2015-2025
3.1 The World Cholesterol-Lowering Drugs Market in 2014
3.1.1 Leading Cholesterol-Lowering Drugs Products
3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market
3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025
3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025
3.3.1 Cholesterol-Lowering Drugs Market Segmentation
3.4 Changing Market Shares by Segment 2015-2025
3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025
4. Leading National Markets, 2015-2025
4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market
4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025
4.1.2 How Will Regional Market Shares Change to 2025?
4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market
4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025
4.2.2 How Will National Market Shares Change to 2025?
4.3 The US Cholesterol-Lowering Drugs Market 2015-2025
4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025
4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.3.2.1 High Prevalence of High Cholesterol in US
4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025
4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025
4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025
4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025
4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025
4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025
4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments
4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025
4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025
4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.2.1.1 Economic Challenges
4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement
4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025
4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025
4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4.1.1 Lower Oil Prices
4.5.4.1.2 No Embargo on Foreign Drugs
4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025
4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.5.1.1 Drug Price Control Order 2014
4.5.5.1.2 Expansion of Healthcare Provision
4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025
4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments
4.6.1.1 Generic Penetration to Reach 60% by 2018?
4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform
5. Statins and Fixed-Dose Combinations: Market and Pipeline 2015-2025
5.1 Statins: Inhibiting HMG-CoA Reductase
5.2 The Statins and Fixed-Dose Combinations Market in 2014
5.3 Statins and Fixed-Dose Combinations: Market Forecast 2015-2025
5.4 How Will Market Shares of Products Change to 2025?
5.5 Crestor (Rosuvastatin, AstraZeneca)
5.5.1 Crestor: Historical Sales Estimate 2009-2014
5.5.2 Crestor: Sales Forecast 2015-2025
5.5.3 Generic Competition for Crestor
5.6 Lipitor (Atorvastatin, Pfizer)
5.6.1 Lipitor: Historical Sales Estimate 2009-2014
5.6.2 Lipitor: Sales Forecast 2015-2025
5.7 Livalo (Pitavastatin, Kowa)
5.7.1 Livalo: Sales Forecast 2015-2025
5.8 Lescol and Lescol XL (Fluvastatin, Novartis)
5.8.1 Lescol/Lescol XL: Sales Forecast 2015-2025
5.9 Zocor (Simvastatin, Merck)
5.9.1 Zocor: Sales Forecast 2015-2025
5.10 Fixed-Dose Combinations
5.11 Vytorin (Simvastatin/Ezetimibe, Merck)
5.11.1 Vytorin: Sales Forecast 2015-2025
5.12 Caduet (Atorvastatin/Amlodipine, Pfizer)
5.12.1 Caduet: Sales Forecast 2015-2025
6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025
6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview
6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014
6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares of Products Change to 2025?
6.5 Zetia (Ezetimibe, Merck)
6.5.1 The ENHANCE Study: No Additional Benefit
6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk
6.5.3 Zetia: Sales Forecast 2015-2025
6.6 Welchol (Colesevelam, Daiichi Sankyo)
6.6.1 Threat of Imminent Generic Competition for Welchol
6.6.2 Welchol: Sales Forecast 2015-2025
6.7 Tricor (Fenofibrate, AbbVie)
6.7.1 Generic Erosion of Tricor Sales
6.7.2 Tricor: Sales Forecast 2015-2025
7. PCSK9 Inhibitors: Market and Pipeline 2015-2025
7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?
7.2 PCSK9 in Clinical Trials
7.3 PCSK9 Inhibitors and Statins
7.4 PCSK9 Inhibitors: Market Forecast 2015-2025
7.5 How Will Market Shares of Products Change to 2025?
7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025
7.7 Praluent (Alirocumab, Sanofi/Regeneron)
7.7.1 Praluent: Sales Forecast 2015-2025
7.8 Repatha (Evolocumab, Amgen)
7.8.1 GAUSS-2
7.8.2 RUTHERFORD-2
7.8.3 LAPLACE-2
7.8.4 Repatha: Sales Forecast 2015-2025
7.9 RN316 (Bococizumab, Pfizer)
7.9.1 RN316: Sales Forecast 2015-2025
7.10 Oral PCSK9 Inhibitor (Pfizer)
7.11 PF-06427878 (Pfizer)
7.12 PCSK9 Vaccine (Pfizer)
7.13 SX-PCK9 (Serometrix)
7.14 Discontinued Pipeline Products
7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)
7.14.2 LY3015014 (Eli Lilly)
8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025
8.1 Novel Cholesterol-Lowering Drugs: Overview
8.2 Novel Cholesterol-Lowering Drugs Market in 2014
8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025
8.4 How Will Market Shares of Products Change to 2025?
8.5 CETP Inhibitors: Overview
8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025
8.5.2 MK-0859 (Anacetrapib, Merck)
8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025
8.5.3 Dalcetrapib (DalCor)
8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)
8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy’s Laboratories)
8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)
8.5.7 K-312 (CETP Inhibitor, Kowa)
8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025
8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)
8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025
8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025
8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)
8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy
8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025
8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025
8.8.1 K-877 (PPAR-α Agonist, Kowa)
8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)
8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)
8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)
8.9 Discontinued Pipeline Products
8.9.1 Torcetrapib
8.9.2 LY2484595 (Evacetrapib)
9. Leading Companies in the Cholesterol-Lowering Drugs Market
9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014
9.1.1 Leading Companies: Market Forecast 2015-2025
9.1.2 How Will Leading Companies’ Market Shares Change to 2025?
9.2 AstraZeneca
9.2.1 AstraZeneca: Cholesterol-Lowering Drugs
9.2.2 AstraZeneca: Sales Forecast 2015-2025
9.2.3 AstraZeneca: Recent Developments
9.2.3.1 Cholesterol Awareness Initiative in America
9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid
9.3 Merck
9.3.1 Merck: Cholesterol-Lowering Drugs
9.3.2 Merck: Sales Forecast 2015-2025
9.3.3 Merck: Recent Developments
9.3.3.1 Bayer Acquires Merck’s Consumer Health Business
9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial
9.4 Pfizer
9.4.1 Pfizer: Cholesterol-Lowering Drugs
9.4.2 Pfizer: Sales Forecast 2015-2025
9.4.3 Pfizer: Recent Developments
9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program
9.4.3.2 Development of Oral PCSK9 Inhibitor
9.5 Kowa
9.5.1 Kowa: Cholesterol-Lowering Drugs
9.5.2 Kowa: Sales Forecast 2015-2025
9.5.3 Kowa: Recent Developments
9.5.3.1 Development of K-312
9.5.3.2 Development of K-887
9.6 Daiichi Sankyo
9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs
9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025
9.6.3 Daiichi Sankyo: Recent Developments
9.6.3.1 Staff Reduction at US Operation
9.7 AbbVie
9.7.1 AbbVie: Cholesterol-Lowering Drugs
9.7.2 AbbVie: Sales Forecast 2015-2025
9.7.3 AbbVie: Recent Developments
9.7.3.1 Possible Marketing Cost Reductions
9.8 Novartis
9.8.1 Novartis: Cholesterol-Lowering Drugs
9.8.2 Novartis: Sales Forecast 2015-2025
9.9 Sanofi
9.9.1 Sanofi: Cholesterol-Lowering Drugs
9.9.2 Sanofi: Sales Forecast 2015-2025
9.9.3 Sanofi: Recent Developments
9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals
9.10 Amgen
9.10.1 Amgen: Cholesterol-Lowering Drugs
9.10.2 Amgen: Sales Forecast 2015-2025
9.10.3 Amgen: Recent Developments
9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent
10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025
10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market
10.2 Strengths
10.2.1 Strong Pipeline
10.2.2 High Profile Encouraging Healthcare Provision
10.3 Weaknesses
10.3.1 Increasing Generic Penetration
10.3.2 Approved Indications Limited for New Products
10.4 Opportunities
10.4.1 Increasing Prevalence in Emerging Markets
10.4.2 Possible Additional Indications
10.5 Threats
10.5.1 Patent Expiry
10.5.2 Cost-Containment
10.6 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market
10.6.1 Rivalry among Competitors [High]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Low]
10.6.4 Power of Buyers [Medium]
10.6.5 Threat of Substitutes [High]
11. Conclusions
11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015
11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025
12. Glossary
【レポート販売概要】
■ タイトル：コレステロール低下剤の世界市場：PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト■ 英文：Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
■ 発行日：2015年11月
■ 調査会社：visiongain
■ 商品コード：VGAIN5112512
■ 調査対象地域：グローバル
- BOM（部品表）ソフトウェアの世界市場2016-2020About the Bill of Materials (BOM) Software Market The BOM is a list of raw materials, parts, and components and the quantity of them required to manufacture a product. There are three types of BOM: • Manufacturing BOM: It is a list of parts required to manufacture a complete product. • Engineering BOM: It is a list of parts required as per the engineering drawing notes, which are made prior to man …
- フラットベッドセミトレーラーの世界市場：コンボフラットベッドセミトレーラー、スチール製フラットベッドセミトレーラー、アルミ製フラットベッドセミトレーラーGlobal Flatbed Semi-Trailer Market: About this market Technavio’s flatbed semi-trailer market analysis considers sales from steel flatbed semi-trailer, combo flatbed semi-trailer, and aluminum flatbed semi-trailers. Our analysis also considers the sales of a flatbed semi-trailer in APAC, Europe, North America, South America, and MEA. In 2018, the combo flatbed semi-trailer segment had a significan …
- 心臓モニタリング＆心臓律動管理デバイスの世界市場予測：心電図（ECG）デバイス、安静時ECG、負荷心電図、ホルターモニター、心拍出量モニタリング（COM）デバイス、埋込み可能ループレコーダ、イベントモニタ、除細動器、ペースメーカー、CRT-D、CRT-PThe global cardiac monitoring market is projected to reach USD 28.00 Billion by 2021 from USD 22.19 Billion in 2016, at a CAGR of 4.8% from 2016 to 2021. Growth in this market is mainly driven by factors such as rising incidence of cardiovascular disorders, growing use of mobile cardiac telemetry, and rise in private institutional nursing and home care. However, dearth of skilled healthcare profes …
- Nobel Biocare Holding AG：市場シェア分析Nobel Biocare Holding AG Market Share Analysis Summary GlobalData’s new report, “Nobel Biocare Holding AG Market Share Analysis” provides in-depth information on Nobel Biocare Holding AG’s market position in the different medical equipment markets it operates in. The report provides Nobel Biocare Holding AG market share information in three key market categories – Dental Implants, CAD/CAM Dental S …
- テレコムIoTの世界市場2016-2020About Telecom IoT The IoT is a network of physical objects that are interconnected and can communicate among themselves as well as with the internal and external environments. It connects hardware devices, software, and communication and IT services. It creates smart communication environments such as smart homes, smart shopping, smart transportation, and smart healthcare. It is an emerging ecosys …
- 自動車トルクベクタリング装置の世界市場2017-2021About Automotive Torque Vectoring SystemTorque vectoring as a technology is developed as an addition to the basic or standard differential. Hence, this technology performs the basic tasks of a usual differential, as well as transmitting torque independently to the driving wheels. This ability to transfer independent torque generally results in the improvement of vehicular handling and traction. To …
- ジェット燃料添加剤の世界市場2015-2019Technavio’s market research analyst predicts the jet fuel additives market to witness a steady growth at a CAGR of around 7% during the forecast period. The lower oil prices and the need for fuel efficient aircrafts are the key drivers behind the growth of this market. The use of high-performance additives helps in reducing the costs of maintenance, reduce coking issues and provide optimum high-pe …
- 無機顔料の世界市場2017-2021ABSTRACTAbout Inorganic Pigment Inorganic pigments are oxides, sulfides, oxide hydroxides, silicates, sulfates, or carbonates barring a few exceptions. They have a definite crystal structure and often consist single component particles. The global inorganic pigments market is expected to grow considerably during the forecast period. The fact that inorganic pigments are an indispensable part of the …
- 再発性多発性硬化症(RMS)治療のグローバル臨床試験動向（2014年下半期）Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2014" provides data on the Relapsing Multiple Sclerosis (RMS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsing Multiple Sclerosis (RMS). …
- モノマー市場動向：May 2013Monomer World - May 2013 Summary Global monomer prices were relatively stable in May 2013 compared to the past few months since the beginning of 2013. Monomer supply and demand were balanced in Asia-Pacific and North America. In Europe, ethylene prices decreased spectacularly in the first half of the month; however, they recovered in the second half and traded at $100 less than April’s average pri …
- Topical Clonidine（神経因性疼痛）：医薬品市場予測及び分析（～2022）Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. A …
- 世界のフラン樹脂市場2015The Global Furan Resins Industry Report 2015 is a professional and in-depth study on the current state of the Furan Resins industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Furan Resins market analysis is provided for the international markets including development trends, competitive landscape analy …
- 石油・ガス産業における交流電動機の世界市場予測（～2023年）“The AC electric motor sales in oil & gas market is projected to grow at a CAGR of 4.62%, from 2018 to 2023.” The AC electric motor sales in oil & gas market is projected to reach USD 13.2 billion by 2023, from an estimated USD 10.5 billion in 2018, at a CAGR of 4.62%. This can be attributed to the growth of the technological developments in the oil & gas industry. Increasing automation in the oil …
- 先進エネルギー貯蔵システムの世界市場：リチウムイオン電池、PHS、NAS電池、CASE、フロー電池、スーパーキャパシタAdvanced energy storage systems market is projected to grow at a CAGR of 4.4% during the forecast period to reach a value of USD 15.9 Million by 2020. The growth is attributed to energy arbitrage opportunities, increase in renewable energy installations, and growth of the electric vehicles market across the globe. Advanced energy storage systems market, on the basis of application, has been catego …
- 医療用ガス・装置の世界市場：酸素、窒素、亜酸化窒素、ヘリウム、ガス混合物、送達システム、極低温冷凍装置、酸素濃縮器The global medical gases market is expected to reach USD 19.96 Billion by 2021 from USD 13.58 Billion in 2016, at a CAGR of 8.0% during the forecast period. Increasing prevalence of respiratory diseases, growing home healthcare market, rising aging population, implementation of the U.S. Food and Drug Administration (FDA) Safety and Innovation Act, rapid urbanization, high prevalence of tobacco smo …
